Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2018-09-28 eCollection Date: 2018-04-01 DOI:10.2217/hep-2018-0001

Nikolaos Galanakis, Elias Kehagias, Nikolas Matthaiou, Dimitrios Samonakis, Dimitrios Tsetis

引用次数: 23

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common type of malignancy. Several therapies are available for HCC and are determined by stage of presentation, patient clinical status and liver function. Local-regional treatment options, including transcatheter arterial chemoembolization, radiofrequency ablation or microwave ablation, are safe and effective for HCC but are accompanied by limitations. The synergistic effects of combined transcatheter arterial chemoembolization and radiofrequency ablation/microwave ablation may overcome these limitations and improve the therapeutic outcome. The purpose of this article is to review the current literature on these combined therapies and examine their efficacy, safety and influence on the overall and recurrence-free survival in patients with HCC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经导管动脉化疗栓塞联合射频或微波消融治疗肝细胞癌:综述。

肝细胞癌(HCC)是第六大最常见的恶性肿瘤。肝细胞癌有几种治疗方法，根据表现阶段、患者临床状态和肝功能而定。局部区域治疗方案，包括经导管动脉化疗栓塞、射频消融或微波消融，对HCC是安全有效的，但也有局限性。经导管动脉化疗栓塞联合射频消融/微波消融的协同作用可能克服这些局限性，改善治疗效果。本文的目的是回顾目前关于这些联合治疗的文献，并检查它们的有效性、安全性以及对HCC患者总生存率和无复发生存率的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.